As AI becomes embedded across pharmacovigilance, the skills required of safety scientists are rapidly evolving. This article examines the shifting balance between human expertise and AI-enabled tools, outlining the competencies, training pathways, and cultural changes needed to prepare tomorrow’s hybrid PV workforce.
HEOR is taking on a broader role within modern CROs. In this podcast conversation hosted by HealthEconomics.com, UBC's Aaron Berger and Dr. Mir Sohail Fazeli discuss how integrated evidence delivery, strong methodology, and real‑world context are shaping the next generation of evidence strategies.
The history of depression treatment reflects a centuries-old tension between mind and body—and how we conceptualize the condition has always shaped how we treat it. Today, with up to 30% of patients classified as treatment-resistant, psychedelic-assisted therapies are attracting serious scientific and regulatory attention. But emerging evidence suggests that the therapeutic context surrounding these treatments—relationships, setting, and social environment—may matter as much as the compounds themselves.
As AI becomes embedded across pharmacovigilance, the skills required of safety scientists are rapidly evolving. This article examines the shifting balance between human expertise and AI-enabled tools, outlining the competencies, training pathways, and cultural changes needed to prepare tomorrow’s hybrid PV workforce.
HEOR is taking on a broader role within modern CROs. In this podcast conversation hosted by HealthEconomics.com, UBC's Aaron Berger and Dr. Mir Sohail Fazeli discuss how integrated evidence delivery, strong methodology, and real‑world context are shaping the next generation of evidence strategies.
The history of depression treatment reflects a centuries-old tension between mind and body—and how we conceptualize the condition has always shaped how we treat it. Today, with up to 30% of patients classified as treatment-resistant, psychedelic-assisted therapies are attracting serious scientific and regulatory attention. But emerging evidence suggests that the therapeutic context surrounding these treatments—relationships, setting, and social environment—may matter as much as the compounds themselves.
One in four drugs traces its origin to serendipity—unexpected discoveries that changed medicine forever. From penicillin to GLP-1s now projected to reach $100 billion by 2030, the most transformative treatments often emerge when researchers pay attention to "off-target" effects. As AI reshapes drug development, human observation and patient-centered design remain our most powerful tools for breakthrough discoveries.
Judy Lytle
Executive Director, Evidence Development Study Solutions
UBC talked with Josh Hardman, founder of Psychedelic Alpha, to discuss the evolving landscape of psychedelic drug development—from shifting regulatory expectations to the role of psychotherapy and the impact of stigma on patient access. Hardman shares a clear-eyed perspective on where the field stands today, the scientific rigor needed to advance it, and what he’s watching most closely as the industry moves toward potential first approvals.
As we look ahead to 2026, patient access and support services face growing complexity—from affordability challenges and evolving care models to the rise of specialty therapies. This blog explores the key trends shaping the healthcare landscape and offers strategic solutions, including AI-powered innovation, digital transformation, and partnerships that drive better outcomes. Discover how UBC is leading the way with patient-first strategies to simplify the patient and product journey.
AI is no longer just a buzzword—it’s a practical tool shaping how we work every day. Learn how UBC leverages AI models to streamline tasks, enhance decision-making, and maintain compliance.
Modern medical record retrieval is transforming real-world evidence. Datavant’s approach combines nationwide reach, deep data connectivity, and high record yields to deliver comprehensive, research-ready datasets.
UBC attended the 2025 NORD Rare Diseases & Orphan Products Breakthrough Summit, where patient voices, scientific innovation, and regulatory expertise converged to shape the future of rare-disease research. Learn what inspired us and how we’re advancing real-world evidence, patient partnerships, and innovative trial designs to accelerate progress for the rare-disease community.
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.